1. Scrip

LegoChem Brings Late Christmas Cheer With $1.7bn ADC Deal

Janssen Gets Worldwide Rights To Trop2-Directed ADC

 
• By Jung Won Shin

LegoChem Biosciences has sealed yet another sizable out-licensing agreement with a global big pharma firm, this time with Janssen, underlining the continued keen global interest in ADCs.

christmas gift
LegoChem/Janssen ADC Deal Biggest So Far For Korean Firm • Source: Shutterstock

More signs of improvement in South Korean biopharma alliances emerged right at the end of 2023, with LegoChem Biosciences, Inc. announcing an up to $1.7bn antibody-drug conjugate (ADC) deal with Janssen Biotech Inc. just after Christmas. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia